217 related articles for article (PubMed ID: 11927930)
1. New anti-HSV therapeutics target the helicase-primase complex.
Crumpacker CS; Schaffer PA
Nat Med; 2002 Apr; 8(4):327-8. PubMed ID: 11927930
[No Abstract] [Full Text] [Related]
2. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
[TBL] [Abstract][Full Text] [Related]
3. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.
Kleymann G; Fischer R; Betz UA; Hendrix M; Bender W; Schneider U; Handke G; Eckenberg P; Hewlett G; Pevzner V; Baumeister J; Weber O; Henninger K; Keldenich J; Jensen A; Kolb J; Bach U; Popp A; Mäben J; Frappa I; Haebich D; Lockhoff O; Rübsamen-Waigmann H
Nat Med; 2002 Apr; 8(4):392-8. PubMed ID: 11927946
[TBL] [Abstract][Full Text] [Related]
4. Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections.
Biswas S; Sukla S; Field HJ
Future Med Chem; 2014 Jan; 6(1):45-55. PubMed ID: 24358947
[TBL] [Abstract][Full Text] [Related]
5. New antiviral drugs that target herpesvirus helicase primase enzymes.
Kleymann G
Herpes; 2003 Aug; 10(2):46-52. PubMed ID: 14577954
[TBL] [Abstract][Full Text] [Related]
6. A short commentary on the review by Weller and Kuchta: the DNA helicase-primase complex as a target for herpes virus infection.
Field HJ
Expert Opin Ther Targets; 2013 Oct; 17(10):1113-4. PubMed ID: 24044544
[No Abstract] [Full Text] [Related]
7. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.
Collot M; Rouard C; Brunet C; Agut H; Boutolleau D; Burrel S
Antiviral Res; 2016 Apr; 128():1-6. PubMed ID: 26826441
[TBL] [Abstract][Full Text] [Related]
8. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus.
Field HJ; Biswas S
Drug Resist Updat; 2011 Feb; 14(1):45-51. PubMed ID: 21183396
[TBL] [Abstract][Full Text] [Related]
9. Helicase-primase as a target of new therapies for herpes simplex virus infections.
James SH; Larson KB; Acosta EP; Prichard MN
Clin Pharmacol Ther; 2015 Jan; 97(1):66-78. PubMed ID: 25670384
[TBL] [Abstract][Full Text] [Related]
10. The structure and function of the HSV DNA replication proteins: defining novel antiviral targets.
Matthews JT; Terry BJ; Field AK
Antiviral Res; 1993 Feb; 20(2):89-114. PubMed ID: 8384825
[TBL] [Abstract][Full Text] [Related]
11. Drugs in development for herpes simplex and varicella zoster virus.
Birkmann A; Zimmermann H
Clin Pharmacol Ther; 2017 Jul; 102(1):30-32. PubMed ID: 28160282
[TBL] [Abstract][Full Text] [Related]
12. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
[TBL] [Abstract][Full Text] [Related]
13. Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase.
Liuzzi M; Kibler P; Bousquet C; Harji F; Bolger G; Garneau M; Lapeyre N; McCollum RS; Faucher AM; Simoneau B; Cordingley MG
Antiviral Res; 2004 Dec; 64(3):161-70. PubMed ID: 15550269
[TBL] [Abstract][Full Text] [Related]
14. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.
Wozniak MA; Frost AL; Itzhaki RF
Antiviral Res; 2013 Sep; 99(3):401-4. PubMed ID: 23867133
[TBL] [Abstract][Full Text] [Related]
15. Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease.
Kristofferson A; Ericson AC; Sohl-Akerlund A; Datema R
J Gen Virol; 1988 Jun; 69 ( Pt 6)():1157-66. PubMed ID: 2838569
[TBL] [Abstract][Full Text] [Related]
16. Recurrent herpes simplex virus hepatitis after liver retransplantation despite acyclovir therapy.
Longerich T; Eisenbach C; Penzel R; Kremer T; Flechtenmacher C; Helmke B; Encke J; Kraus T; Schirmacher P
Liver Transpl; 2005 Oct; 11(10):1289-94. PubMed ID: 16184558
[TBL] [Abstract][Full Text] [Related]
17. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
[TBL] [Abstract][Full Text] [Related]
18. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target.
Biswas S; Kleymann G; Swift M; Tiley LS; Lyall J; Aguirre-Hernández J; Field HJ
J Antimicrob Chemother; 2008 May; 61(5):1044-7. PubMed ID: 18299638
[TBL] [Abstract][Full Text] [Related]
19. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.
Biswas S; Tiley LS; Zimmermann H; Birkmann A; Field HJ
Antiviral Res; 2008 Oct; 80(1):81-5. PubMed ID: 18539344
[TBL] [Abstract][Full Text] [Related]
20. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture.
Biswas S; Jennens L; Field HJ
Arch Virol; 2007; 152(8):1489-500. PubMed ID: 17404685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]